
January 14 2026 - JPM26: AstraZeneca's $80B revenue target 'very …
5 days ago · Confidence is on full display at JPM, as companies talk up revenue targets, pipeline momentum, and dealmaking strength—tempered by ongoing regulatory and pricing realities.JPM26: …
AstraZeneca | Cafepharma
5 days ago · AstraZeneca on Thursday appointed company insider Rick Suarez as the head of its U.S. biopharmaceuticals unit to lead the drugmaker's $50 billion investment plan in the company's largest …
AstraZeneca | Cafepharma Message Boards | Pharma Sales, Device …
Aug 1, 2022 · Anonymous board for AstraZeneca. We’ve seen a growing number of threads touching on AI tools—everything from ChatGPT to internal company initiatives—but mostly in bits and pieces. …
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Anonymous discussion boards for pharmaceutical sales, medical/device sales, lab/diagnostics sales
July 24 2025 - AstraZeneca drug acquired in Alexion deal succeeds in ...
Jul 24, 2025 · AstraZeneca drug acquired in Alexion deal succeeds in autoimmune disease trialAstraZeneca boardPharma giant Roche sees income soar in first halfRoche boardNovartis to pay …
Cafepharma - Home | pharma sales, device sales, lab sales | Cafepharma
3 days ago · Friday’s CP Today spans JPM takeaways, market moves, M&A chatter, and lingering regulatory questions as the week comes to a close. Novo shares jump on ‘encouraging’ Wegovy pill …
Cafepharma News
Latest news and updates on pharmaceutical and medical sales, including breakthrough treatments and industry trends.
AstraZeneca’s Fasenra meets primary endpoint in Phase III rare ...
Sep 12, 2023 · The Phase III trial compared the efficacy of Fasenra with the standard treatment of GSK’s Nucala in patients with eosinophilic granulomatosis with polyangiitis.
Pfizer | Cafepharma Message Boards | Pharma Sales, Device Sales, Lab …
Feb 23, 2025 · Anonymous board for Pfizer. We’ve seen a growing number of threads touching on AI tools—everything from ChatGPT to internal company initiatives—but mostly in bits and pieces. We’re …
AstraZeneca Deepens Cancer Cell Therapy Portfolio with Neogene …
AstraZeneca and Neogene Therapeutics have entered into a definitive acquisition agreement in which AstraZeneca will buy all outstanding equity in the smaller company. The deal aims to advance T-cell …